GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.

Research output: Contribution to journalJournal articleResearchpeer-review

Small bowel motility was studied in rats at increasing (1-20 pmol/kg/min) intravenous doses of either glucagon-like peptide-1 (GLP-1) or glucagon-like peptide-2 (GLP-2) alone, or in combination in the fasted and fed state. There was a dose-dependent inhibitory action of GLP-1 on the migrating myoelectric complex (MMC), where the dose of 5 pmol/kg/min induced an increased MMC cycle length. No effect was seen with GLP-2 alone, but the combination of GLP-1 and GLP-2 induced a more pronounced inhibitory effect, with significant increase of the MMC cycle length from a dose of 2 pmol/kg/min. During fed motility, infusion of GLP-1 resulted in an inhibition of spiking activity compared to control. In contrast, infusion of GLP-2 only numerically increased spiking activity compared to control, while the combination of GLP-1 and GLP-2 resulted in no change compared to control. In summary, this study demonstrates an additive effect of peripheral administration of GLP-1 and GLP-2 on fasted small bowel motility. In the fed state, GLP-1 and GLP-2 seem to display counter-balancing effects on motility of the small intestine.
Original languageEnglish
JournalRegulatory Peptides
Volume107
Issue number1-3
Pages (from-to)129-35
Number of pages6
ISSN0167-0115
Publication statusPublished - 2002

Bibliographical note

Keywords: Animals; Blood Glucose; Drug Interactions; Eating; Electromyography; Fasting; Gastrointestinal Motility; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Injections, Intravenous; Insulin; Intestine, Small; Male; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley

ID: 8418312